Shenzhen Salubris Pharmaceuticals Co., Ltd. 002294.SZ Stock
Shenzhen Salubris Pharmaceuticals Co., Ltd. Price Chart
Shenzhen Salubris Pharmaceuticals Co., Ltd. 002294.SZ Financial and Trading Overview
Contents
- Shenzhen Salubris Pharmaceuticals Co., Ltd. Price Chart
- Shenzhen Salubris Pharmaceuticals Co., Ltd. 002294.SZ Financial and Trading Overview
- Valuation Measures
- Trading Information
- Financial Highlights
- Profile of Shenzhen Salubris Pharmaceuticals Co., Ltd.
- Q&A For Shenzhen Salubris Pharmaceuticals Co., Ltd. Stock
| Shenzhen Salubris Pharmaceuticals Co., Ltd. stock price | 29.18 CNY |
| Previous Close | 32.55 CNY |
| Open | 32.69 CNY |
| Bid | 32.71 CNY x 0 |
| Ask | 32.73 CNY x 0 |
| Day's Range | 32.62 - 33.66 CNY |
| 52 Week Range | 22.3 - 39.33 CNY |
| Volume | 3.62M CNY |
| Avg. Volume | 3.38M CNY |
| Market Cap | 36.48B CNY |
| Beta (5Y Monthly) | 0.655821 |
| PE Ratio (TTM) | 58.428574 |
| EPS (TTM) | 0.52 CNY |
| Forward Dividend & Yield | 0.5 (1.54%) |
| Ex-Dividend Date | May 9, 2023 |
| 1y Target Est | 36.2 CNY |
002294.SZ Valuation Measures
| Enterprise Value | 32.76B CNY |
| Trailing P/E | 58.428574 |
| Forward P/E | 38.046513 |
| PEG Ratio (5 yr expected) | 2.42 |
| Price/Sales (ttm) | 10.621408 |
| Price/Book (mrq) | 4.380774 |
| Enterprise Value/Revenue | 9.539 |
| Enterprise Value/EBITDA | 38.096 |
Trading Information
Shenzhen Salubris Pharmaceuticals Co., Ltd. Stock Price History
| Beta (5Y Monthly) | 0.655821 |
| 52-Week Change | 19.75% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 39.33 CNY |
| 52 Week Low | 22.3 CNY |
| 50-Day Moving Average | 35.28 CNY |
| 200-Day Moving Average | 32.89 CNY |
002294.SZ Share Statistics
| Avg. Volume (3 month) | 3.38M CNY |
| Avg. Daily Volume (10-Days) | 2.57M CNY |
| Shares Outstanding | 1.11B |
| Float | 413.95M |
| Short Ratio | N/A |
| % Held by Insiders | 62.44% |
| % Held by Institutions | 8.54% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0.5 |
| Trailing Annual Dividend Yield | 1.53% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0.72730005 |
| Last Split Factor | 16:10 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 17.77% |
| Operating Margin (ttm) | 16.00% |
| Gross Margin | 70.14% |
| EBITDA Margin | 25.03% |
Management Effectiveness
| Return on Assets (ttm) | 3.54% |
| Return on Equity (ttm) | 7.46% |
Income Statement
| Revenue (ttm) | 3.43B CNY |
| Revenue Per Share (ttm) | 3.11 CNY |
| Quarterly Revenue Growth (yoy) | -5.099% |
| Gross Profit (ttm) | N/A |
| EBITDA | 859.89M CNY |
| Net Income Avi to Common (ttm) | 610.48M CNY |
| Diluted EPS (ttm) | 0.56 |
| Quarterly Earnings Growth (yoy) | -11.099% |
Balance Sheet
| Total Cash (mrq) | 2.76B CNY |
| Total Cash Per Share (mrq) | 2.53 CNY |
| Total Debt (mrq) | 90.81M CNY |
| Total Debt/Equity (mrq) | 1.11 CNY |
| Current Ratio (mrq) | 3.465 |
| Book Value Per Share (mrq) | 7.469 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 930.92M CNY |
| Levered Free Cash Flow (ttm) | -372621920 CNY |
Profile of Shenzhen Salubris Pharmaceuticals Co., Ltd.
| Country | China |
| State | N/A |
| City | Shenzhen |
| Address | NEO Greenview Plaza, Block B |
| ZIP | N/A |
| Phone | 86 755 8386 7888 |
| Website | https://www.salubris.com |
| Industry | Medical Instruments & Supplies |
| Sector(s) | Healthcare |
| Full Time Employees | 3454 |
Shenzhen Salubris Pharmaceuticals Co., Ltd. engages in the research, development, production, and sale of medicines for cardiovascular, anti-diabetic, antineoplastic, and orthopedic therapeutic in China. It offers cardiovascular and cerebrovascular products, such as allisartan isoproxil, benazepril hydrochloride, desloratadine, and clopidogrel bisulfate tablets, as well as bivalirudin and pamidronate disodium injections; recombinant SeV-hFGF2/dF Injection for the treatment of diabetic foot disease; and anti-tumor and orthopedics medicines. The company also provides anti-infection products comprising cefonicid sodium, ceftazidime, ceftriaxone sodium, cefonicid sodium, cefminox sodium, cefuroxime sodium, cefepime hydrochloride, and cefodizime sodium injections, as well as azithromycin dispersible and levetiracetam tablets. In addition, it offers biotechnological drugs, such as recombinant protein and monoclonal antibody drugs. Further, the company is involved in import, licensing-in, and licensing-out medicines for Europe markets. The company was founded in 1998 and is headquartered in Shenzhen, China.
Q&A For Shenzhen Salubris Pharmaceuticals Co., Ltd. Stock
What is a current 002294.SZ stock price?
Shenzhen Salubris Pharmaceuticals Co., Ltd. 002294.SZ stock price today per share is 29.18 CNY.
How to purchase Shenzhen Salubris Pharmaceuticals Co., Ltd. stock?
You can buy 002294.SZ shares on the Shenzhen exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Shenzhen Salubris Pharmaceuticals Co., Ltd.?
The stock symbol or ticker of Shenzhen Salubris Pharmaceuticals Co., Ltd. is 002294.SZ.
Which industry does the Shenzhen Salubris Pharmaceuticals Co., Ltd. company belong to?
The Shenzhen Salubris Pharmaceuticals Co., Ltd. industry is Medical Instruments & Supplies.
How many shares does Shenzhen Salubris Pharmaceuticals Co., Ltd. have in circulation?
The max supply of Shenzhen Salubris Pharmaceuticals Co., Ltd. shares is 1.11B.
What is Shenzhen Salubris Pharmaceuticals Co., Ltd. Price to Earnings Ratio (PE Ratio)?
Shenzhen Salubris Pharmaceuticals Co., Ltd. PE Ratio is 56.11538700 now.
What was Shenzhen Salubris Pharmaceuticals Co., Ltd. earnings per share over the trailing 12 months (TTM)?
Shenzhen Salubris Pharmaceuticals Co., Ltd. EPS is 0.52 CNY over the trailing 12 months.
Which sector does the Shenzhen Salubris Pharmaceuticals Co., Ltd. company belong to?
The Shenzhen Salubris Pharmaceuticals Co., Ltd. sector is Healthcare.